Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Poolbeg Pharma Ltd. ( (GB:POLB) ) has shared an announcement.
Poolbeg Pharma announced its audited results for the year ending December 31, 2024, highlighting significant advancements in its drug pipeline and financial health. The company reported a cash balance of £7.8 million and the appointment of Cathal Friel as Executive Chair to enhance performance. POLB 001, a potential oral preventative therapy for cancer immunotherapy-induced CRS, was validated by international experts and presents a market opportunity exceeding US$10 billion. Positive preclinical data and a US patent grant support its development into a Phase 2 clinical trial. Additionally, Poolbeg is advancing its oral GLP-1 program and AI-led drug discovery initiatives, with ongoing discussions with potential partners. These developments underscore Poolbeg’s strategic focus on high-value programs and its potential to create significant shareholder value.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral encapsulated glucagon-like peptide GLP-1R agonist.
Average Trading Volume: 1,108,755
Technical Sentiment Signal: Sell
For detailed information about POLB stock, go to TipRanks’ Stock Analysis page.